Thelansis

Acid Sphingomyelinase Deficiency (ASMD) Market Outlook Thelansis’s “Acid Sphingomyelinase Deficiency (ASMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acid Sphingomyelinase Deficiency (ASMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have...

Acid Sphingomyelinase Deficiency (ASMD) Market Outlook Thelansis’s “Acid Sphingomyelinase Deficiency (ASMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acid Sphingomyelinase Deficiency (ASMD)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acid Sphingomyelinase Deficiency (ASMD) Overview Acid sphingomyelinase deficiency (ASMD), also known historically as Niemann-Pick disease types A, A/B, and B, is a lysosomal storage disease stemming from inadequate activity of the enzyme acid sphingomyelinase (ASM). This insufficiency results in the buildup of varying sphingomyelin levels within the body. ASMD is an inherited dis...

 Acid sphingomyelinase deficiency (ASMD), also known historically as Niemann-Pick disease types A, A/B, and B, is a lysosomal storage disease stemming from inadequate activity of the enzyme acid sphingomyelinase (ASM). This insufficiency results in the buildup of varying sphingomyelin levels within the body. ASMD is an inherited disorder caused by genetic variations that modify specific bodily processes, leading to the onset of the disease. The gene responsible for ASMD is referred to as SMPD1. This condition manifests with foam cell infiltration across different tissues, lipid storage, and a range of clinical symptoms that might overlap. Among these symptoms, pulmonary insufficiency, hepatosplenomegaly, and neurodegeneration stand out. The clinical presentations of ASMD serve as the primary indicators for differentiating this disease, which presents itself as a multi-organ disorder. While hepatosplenomegaly and lung dysfunction are prevalent features in ASMD, ASMD A also involves ...

 Acid Sphingomyelinase Deficiency (ASMD), a rare lysosomal storage disease, is an autosomal recessive genetic disorder caused by mutations in the SMPD1 gene. ASMD has been classified as; Niemann-Pick disease type A (NPD A) and Niemann-Pick disease type B (NPD B). More than 180 SMPD1 mutations are identified in patients with ASMD, including missense, nonsense, frameshift, and splice variants. Diagnoses incidence of ASMD at approximately 0.5 per 100,000 births. NPD A patients have a relatively uniform natural history characterized by severe progressive neurodegeneration in the first year and death typically by three years of age. ·        NPD B has a variable disease course associated with a broad spectrum of disease severity and manifestations. ·        Clinical manifestations of ASMD are hepatosplenomegaly, developmental delay and/or cherry-red maculae, interstitial lung disease, and hyperlipidemia characterized by low...

  Acid sphingomyelinase (ASM) deficiency (ASMD), a rare lysosomal storage disease, is an autosomal recessive genetic disorder caused by mutations in the SMPD1 gene. ASMD has been classified as; Niemann-Pick disease type A (NPD A) and Niemann-Pick disease type B (NPD B).   More than 180 different SMPD1 mutations are identified in patients with ASMD, including missense, nonsense, frameshift mutations, and splice variants. Diagnoses incidence of ASMD at approximately 0.5 per 100,000 births. NPD A patients have a relatively uniform natural history characterized by severe progressive neurodegeneration in the first year and death typically by three years of age. NPD B has a variable disease course associated with a broad spectrum of disease severity and manifestations. Clinical manifestations of ASMD are hepatosplenomegaly, developmental delay, cherry-red maculae, interstitial lung disease, hyperlipidemia characterized by low high-density lipoprotein (HDL) cholesterol, and t...